Jeito Capital funding news – Jeito Capital Announces Significant Participation in upsized $207.5 Million Series C financing in Aviceda Therapeutics

The financing round was co-led by renowned healthcare funds, Omega Funds and TCGX, with significant participation from Jeito Capital and Enavate Sciences, alongside leading investment firms Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, funds managed by abrdn Inc., and Digitalis Ventures.

Read also - Alstin Capital funding news – Munich-based Alstin Capital has Secured €175 Million in Funding

The proceeds will support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trial for AVD-104, its late-clinical stage Lead Program in geographic atrophy (GA) and the expansion into additional ophthalmic indications.

AVD-104’s dual mechanism of action targets immune modulation and complement inhibition and has already shown positive proof-of-concept efficacy in slowing GA lesion growth and preserving/enhancing visual function in a Phase 2a trial completed in early 2024, which underscores its potential for first-in-class efficacy and safety.

Aviceda’s ongoing Phase 2b/3 trial evaluating two doses of AVD-104 versus avacincaptad pegol (Izervay) in patients with GA is fully enrolled, with 12-month primary endpoint data anticipated in the second half of 2025.

Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, said: “Our investment in Aviceda Therapeutics perfectly illustrates our ambition to champion promising late-clinical stage biopharma with the potential to become global market leaders that will make a meaningful difference in patient lives. We have been impressed by Aviceda’s new mechanism whose first positive results represent a new hope for patients. We look forward to starting this new collaboration and bringing our European expertise and global approach to accelerate this transformative therapy for patients with high unmet needs.”

David Guyer, MD, Board Chair of Aviceda, added: “We are pleased to welcome our new board members and a syndicate of top institutional investors. This raise reflects the strong conviction from investors in Aviceda’s lead program AVD-104 for geographic atrophy – a market poised for disruption and an improved standard of care, given current treatments offer limited benefits in visual improvements, lesion control, and safety. With this upsized financing, the company is well-capitalized to advance a pivotal program for AVD-104 in GA.”

About Jeito Capital

Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States.

About Aviceda Therapeutics and AVD-104

Aviceda is a private, clinical stage biotechnology company located in Cambridge, MA, with a proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform and a clinical-stage ophthalmic candidate, AVD-104, for the treatment of geographic atrophy secondary to age-related macular degeneration.